Pazopanib, a new oral angiogenesis inhibitor, showed an interesting activity difficult to work with other small cell lung cancer, US researchers report.Phase II trial 30 out of 35 patients treated for at least two weeks of the preoperative pazopanib saw reduce the size of the tumor, up to a maximum of 85%.
"This is a positive result, which are under consideration," said Prof. Nasser Altorki to New York from Weil Medical College of Cornell University.
"To my knowledge, no other usable angiogenesis inhibitors at an early stage lung cancer, the effects of the results have been published.
Shown here with pazopanib very active drug taking account of the results of this regulation and on the development of lung cancer is running understood the value of this drug, the disease ".
Author: Justin234 Source
No comments:
Post a Comment